Butea monosperma is a South Asian medicinal tree whose bark, flower, and leaf compounds are studied for bone preservation, blood sugar and fat control, and inflammation reduction. Standalone longevity benefits are speculative, resting on rodent and cell studies; human trials only tested herb combinations for kidney stones or parasites. Given low oral absorption, rodent seed organ toxicity, and flower fertility risks, extracts remain early laboratory candidates. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Serum Albumin and Total Protein | Albumin: 3.5–5.0 g/dL; Total Protein: 6.0–8.3 g/dL (standard reference range) | Safety check: detects seed-associated hypoalbuminemia and hypoproteinemia |
| Serum Creatinine and eGFR | Creatinine: 0.6–1.2 mg/dL; eGFR: ≥90 mL/min/1.73 m² (standard reference range) | Safety check: screens for palasonin-associated renal tubular or glomerular injury |
| Hemoglobin and Hematocrit | Hemoglobin: 13.5–17.5 g/dL (men), 12.0–15.5 g/dL (women); Hematocrit: 36%–50% (standard reference range) | Safety check: monitors for seed-associated reductions in red blood cell indices |
| Fasting Blood Glucose and Triglycerides | Glucose: 70–99 mg/dL; Triglycerides: <150 mg/dL (standard reference range) | Safety check and expected-change marker: tracks glycemic and lipid responses or seed-induced hypertriglyceridemia |
| Lumbar Spine and Hip BMD (DXA) and Serum CTX-I | No established target; stabilization or increase in BMD and reduction in CTX-I from individual baseline | Expected-change marker: evaluates osteogenic and antiresorptive response to stem bark fractions |
Cadence: Baseline, 4 and 12 weeks after initiation, and every 6 to 12 months thereafter during cyclic supplementation (with DXA repeated every 12 to 24 months); discontinuation threshold if eGFR drops >15% or albumin (<3.5 g/dL) or hemoglobin falls below normal.